Tabesh Elham, Yadmehr Farzad, Feizi Awat, Khorvash Farzin, Sindarreh Setayesh, Hakamifard Atousa
Gastroenterology and Hepatology Research Center Isfahan University of Medical Sciences Isfahan Iran.
Department of Infectious Diseases, School of Medicine Isfahan University of Medical Sciences Isfahan Iran.
Health Sci Rep. 2024 Jan 25;7(1):e1842. doi: 10.1002/hsr2.1842. eCollection 2024 Jan.
This controlled randomized clinical trial was designed to compare effectiveness, side effects, and severity of symptoms before and after therapy between quadruple (QT) and sequential regimens (SQ) for ().
Patients were randomly allocated into two groups. Group A received a 14-day QT including pantoprazole 40 mg q12 h, bismuth subcitrate 240 mg q12 h, clarithromycin 500 mg q12 h, and amoxicillin 1000 mg q12 h and group B received ST including pantoprazole 40 mg q12 h and amoxicillin 1000 mg q12 h for the initial 5 days followed by pantoprazole 40 mg q12 h, clarithromycin 500 mg q12 h and tinidazole 500 mg q12 h for the next 5 days. Adverse drug reactions and patients' compliance were assessed after finishing the treatment course and also 4 weeks after. All patients were naive, therefore ST and QT were first-line therapies. To evaluate severity of symptoms we used Short-Form Leeds Dyspepsia Questionnaire (SF-LDQ) before taking the first dose of regimens, at the end of therapy, and also 4 weeks after (follow-up).
The mean age in Group A ( = 83) was 48.55 ± 12.56 and 47.24 ± 12.78 in Group B ( = 79). No statistically significant differences were observed between the two groups regarding age, gender, endoscopic findings, and also eradication rate. The analysis demonstrated a significant decrease in SF-LDQ score between baseline and after therapy and baseline and follow-up in both regimen groups. Both regimens were well tolerated by the majority of patients, and there were no significant differences between the two groups in terms of adverse drug reactions.
This study showed that ST can be used as an alternative first-line therapy to QT in patients with infection.
本对照随机临床试验旨在比较四联疗法(QT)和序贯疗法(SQ)治疗()前后的疗效、副作用及症状严重程度。
将患者随机分为两组。A组接受为期14天的QT治疗,包括泮托拉唑40毫克每12小时一次、枸橼酸铋钾240毫克每12小时一次、克拉霉素500毫克每12小时一次以及阿莫西林1000毫克每12小时一次;B组接受序贯疗法,包括初始5天使用泮托拉唑40毫克每12小时一次和阿莫西林1000毫克每12小时一次,随后5天使用泮托拉唑40毫克每12小时一次、克拉霉素500毫克每12小时一次和替硝唑500毫克每12小时一次。在完成疗程后以及4周后评估药物不良反应和患者依从性。所有患者均为初治患者,因此序贯疗法和四联疗法均为一线治疗方案。为评估症状严重程度,在服用首个疗程药物前、治疗结束时以及4周后(随访)使用利兹消化不良简易问卷(SF-LDQ)。
A组(n = 83)的平均年龄为48.55 ± 12.56岁,B组(n = 79)为47.24 ± 12.78岁。两组在年龄、性别、内镜检查结果以及根除率方面均未观察到统计学显著差异。分析表明,两个治疗方案组在基线与治疗后以及基线与随访之间,SF-LDQ评分均显著降低。大多数患者对两种治疗方案耐受性良好,两组在药物不良反应方面无显著差异。
本研究表明,序贯疗法可作为感染患者四联疗法的替代一线治疗方案。